source
- Intercept’s next-generation FXR agonist INT-787 fails Phase 2 trial in alcohol-associated hepatitisIntercept Pharmaceuticals reported that its experimental FXR agonist INT-787 did not demonstrate efficacy in a Phase 2 study of patients with severe alcohol-associated hepatitis. The trial results…
- Study links specific dietary fats to pancreatic cancer risk, highlighting oleic acid as promoter and omega-3s as protectiveResearchers at Yale Cancer Center examined how different types of dietary fat affect pancreatic cancer development in a mouse model. Rather than focusing on total fat intake, the study compared twe…